Amber Glenn previously struggled with depression and sought treatment; she won a team Olympic gold with the U.S. and is competing in the women's singles at the 2026 Winter Olympics.
The third annual AANHPI Night Market will be held Feb. 20 from 5–8 p.m. at Culver City High School and will bring together dozens of Asian American, Native Hawaiian, and Pacific Islander–owned food and goods vendors.
Many Lenten fish fries serve deep-fried fish, and doctors say frequent fried-food intake is linked with higher heart risks; some events offer baked or grilled options and experts noted balancing those meals with healthier choices the rest of the week.
Blueberry is a quiet, affectionate cat who warms up with patience and treats and has prior experience living in a home; he is reported to be comfortable sharing space with other cats.
A CPJ report says 59 Palestinian journalists detained after October 2023 reported widespread abuse in Israeli custody, with most describing physical or sexual violence and severe food deprivation. Many were held under administrative detention and CPJ called for accountability; next steps are undetermined.
A reported Labour proposal would restrict automatic Education, Health and Care Plans (EHCPs) to pupils with severe needs and move decisions and much of the funding for other support to schools from the 2029 academic year.
Michael Zelniker's eight-part series The Struggle for Mother Water was selected for the Berlinale Series Market and documents how billions lack reliable access to safe drinking water.
Microsoft and other hyperscalers are stepping up investment in quantum computing, and Microsoft says machines with commercial value could be operating in data centers by 2029.
Goleta's City Council voted 4-1 to adopt an urgency ordinance that immediately prevents University Mobile Home Park from converting to all-ages and adds a citywide senior mobile home park overlay; the ordinance will expire in 45 days unless extended.
ViiV Healthcare reported that final 48-week data from the LATITUDE phase III trial showed its long-acting injectable, Cabenuva (cabotegravir + rilpivirine), maintained viral load suppression better than daily oral therapy in people with past adherence challenges; the results were published in the New England Journal of Medicine.
